Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 7;13:178. doi: 10.3389/fncel.2019.00178

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Maniezzi, Talpo, Spaiardi, Toselli and Biella.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of TGOT on sIPSCs in PYRs from Otr^+/+ mice. (A) Sample current trace showing sIPSCs recorded during slice perfusion with control saline (CTRL), in the presence of 1 μM TGOT (TGOT) and during wash out (WASH). The upper horizontal bar indicates the time course of drug delivery. (B) Mean current-to-voltage relationship of the sIPSC peak amplitudes (N = 5), showing a reversal potential close to –60 mV. The straight line represents data point fitting. (C) Representative current traces of sIPSCs recorded in the presence of glutamatergic synaptic blockers at a holding potential of 0 mV under control conditions (CTRL), in the presence of 1 μM TGOT (TGOT) and during the co-administration of TGOT with the selective GABA_AR antagonist bicuculline (10 μM) (TGOT + BIC). (D) Representative current trace of sIPSCs recorded in the presence of glutamatergic synaptic blockers, at a holding potential of 0 mV, under control conditions (CTRL), during TGOT administration (TGOT) and during the co-administration of TGOT with the selective murine OtR isoform antagonist SSR126768A (0.1 μM) (TGOT + SSR126768A). (E) Bar plots comparing the mean values of the sIPSC inter-event intervals (N = 23) obtained in control saline and during TGOT application (^∗p < 0.05). (F) Bar plots comparing the mean values of the sIPSC amplitudes (N = 23) obtained in control saline and during TGOT application (^∗p < 0.05). (G) Superimposed average traces of sIPSCs (lined up according to the mid-point of their rise times), recorded in the presence of glutamatergic synaptic blockers, at a holding potential of 0 mV, under control conditions (continuous line, averaging of 25 traces) and during TGOT application (dashed line, averaging of 168 traces whose amplitude was normalized to that of control). (H) Bar plots comparing the mean values (N = 4) of the sIPSC time constant of decay (τ_d) obtained under control conditions and during TGOT application (^∗p < 0.05). (I) Bar plots comparing the mean values (N = 4) of the sIPSC rise time obtained under control conditions and during TGOT application. Vertical bars in (B,E,F,H,I) indicate SE from the mean.